0000937556false00009375562024-11-052024-11-05

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
________________________________________________
FORM 8-K
________________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 5, 2024
masimologoq32019b.jpg
MASIMO CORPORATION
(Exact name of registrant as specified in its charter)
________________________________________________
DE001-3364233-0368882
(State or other jurisdiction
of incorporation)		(Commission
File Number)		(IRS Employer
Identification No.)
52 DiscoveryIrvine,CA92618
(Address of Principal Executive Offices)(Zip Code)
(949)
297-7000
Registrant’s telephone number, including area code:
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities Registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.001 par valueMASIThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐



Item 2.02.Results of Operations and Financial Condition.
On November 5, 2024, Masimo Corporation (the “Company”) issued a press release announcing its financial results for the quarter ended September 28, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report.
In accordance with General Instructions B.2 of Form 8-K, the information in Item 2.02 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 7.01.Regulation FD Disclosure.
In connection with the Company’s conference call scheduled to be held on November 5, 2024, the Company’s Chief Financial Officer will review supplemental information regarding the Company’s financial results for the third quarter 2024 and nine months ended September 28, 2024, as well as the Company’s updated outlook for the remainder of fiscal 2024. The Company is making available to investors supplemental financial information by fiscal quarter for fiscal years 2022 and 2023, along with the first, second and third quarters of 2024, pursuant to the materials furnished as Exhibit 99.2 to this Current Report.
In accordance with General Instructions B.2 of Form 8-K, the information in Item 7.01 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01.Financial Statements and Exhibits.
(d) The following items are filed as exhibits to the Current Report on Form 8-K.
Exhibit
 No.
Description
99.1
99.2
104Cover Page Interactive Data File (embedded within the Inline XBRL document)



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, Masimo Corporation has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
MASIMO CORPORATION
Date: November 5, 2024By:
/s/ MICAH YOUNG
Micah Young
Executive Vice President & Chief Financial Officer
(Principal Financial Officer)


Exhibit 99.1
masimologoq2020.jpg
Masimo Reports Third Quarter 2024 Financial Results
Third Quarter 2024 Highlights:
•
Healthcare revenue of $343.3 million increased 11.5% on a reported basis and 11.7% on a constant currency basis(1);
•GAAP net income per diluted share was $0.18; and
•
Non-GAAP(1) net income per diluted share was $0.98.
Irvine, California, November 5, 2024 - Masimo Corporation (Nasdaq: MASI) today announced its financial results for the third quarter ended September 28, 2024.
Third Quarter 2024 Results
Consolidated revenue was $504.6 million, comprised of healthcare revenue of $343.3 million and non-healthcare revenue of $161.3 million. Shipments of noninvasive technology boards and instruments were 60,500. GAAP operating income was $30.1 million and non-GAAP(1) operating income was $80.8 million. GAAP net income was $9.8 million, or $0.18 per diluted share. Non-GAAP(1) net income was $52.9 million, or $0.98 per diluted share.
Michelle Brennan, Interim Chief Executive Officer of Masimo, said, “We are pleased to report strong third quarter performance, driven by our core healthcare segment. We appreciate the commitment and energy of our employees, which has resulted in a seamless transition since our Annual Meeting with no disruption to our business or departures of critical talent. Our focus is on positioning Masimo to achieve its significant long-term growth potential by capitalizing on the many opportunities we see ahead of us, including through our ongoing review of the product portfolio and R&D projects. We are allocating resources to fewer projects, concentrating on sizable market opportunities that address clear unmet needs, and reducing spending in areas that are not contributing to our long-term growth objectives. We are also progressing on our strategic review of the consumer business and are focused on delivering the best outcome for our shareholders. We are confident in our position as we approach the end of 2024, as demonstrated by our increased full-year non-GAAP operating margin and EPS guidance. With the support of our talented team and our newly expanded Board, we will continue to execute on our strategy while enhancing shareholder value as we look to next year and beyond.”
2024 Financial Guidance
The Company provided the following non-GAAP(2) estimates for its fourth quarter 2024 and updated full-year 2024 guidance:
(in millions, except earnings per diluted share)
Q4 2024
Guidance(3)
FY 2024
Updated Guidance(3)
FY 2024
Prior Guidance(4)
Consolidated revenue
$581 to $611
$2,075 to $2,105
$2,085 to $2,135
Healthcare revenue
$363 to $373
$1,390 to $1,400
$1,385 to $1,405
Non-healthcare revenue
$218 to $238
$685 to $705
$700 to $730
Non-GAAP(2) operating income
$103 to $114
$325 to $336
$317 to $330
Non-GAAP(2) earnings per diluted share
$1.35 to $1.50
$3.95 to $4.10
$3.80 to $4.00
____________________________
(1)    Represents a non-GAAP financial measure for which a reconciliation to the most directly comparable GAAP financial measure is included in this press release.
(2)    Financial guidance includes forward-looking non-GAAP financial measures for which reconciliations to the most directly comparable GAAP financial measures are not available without unreasonable efforts. See “Forward-Looking Non-GAAP Financial Measures” below, which identifies the information that is unavailable without unreasonable efforts and provides additional information. It is probable that forward-looking non-GAAP financial measures may be materially different from the corresponding GAAP financial measures.
(3)    Guidance provided November 5, 2024.
(4)    Guidance provided August 6, 2024.
-1-

Conference Call
The Company will conduct its third quarter 2024 investor conference call today, November 5, 2024 at 4:30 p.m. Eastern Time. To register for the conference call and receive the dial-in number, please use the following link: https://registrations.events/direct/Q4I40728936. A replay of the webcast and conference call will be available shortly after the conclusion of the call and will be archived on the Company’s website.
Website Information
To access important information relating to Masimo’s third quarter 2024 investor conference call, including the audio webcast and investor presentation, please visit the Investor Relations section of Masimo’s website at https://investor.masimo.com.
Non-GAAP Financial Measures
The non-GAAP financial measures contained herein are a supplement to the corresponding financial measures prepared in accordance with U.S. GAAP. The non-GAAP financial measures presented exclude the items described below. Management believes that adjustments for these items assist investors in making comparisons of period-to-period operating results. Furthermore, management also believes that these items are not indicative of the Company’s on-going operating performance. These non-GAAP financial measures have certain limitations in that they do not reflect all of the costs associated with the operations of the Company’s business as determined in accordance with GAAP.
Therefore, investors should consider non-GAAP financial measures in addition to, and not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. The non-GAAP financial measures presented by the Company may be different from the non-GAAP financial measures used by other companies.
The Company has presented the following non-GAAP measures to assist investors in understanding the Company’s net operating results on an on-going basis: (i) constant currency revenue growth percentage, (ii) non-GAAP net income (prior definition and updated definition), (iii) non-GAAP (net income) earnings per diluted share (prior definition and updated definition) and (iv) non-GAAP operating income/margin (prior definition and updated definition). These non-GAAP financial measures may also assist investors in making comparisons of the Company’s operating results with those of other companies. Management believes constant currency revenue growth, non-GAAP operating income/margin, non-GAAP net income and non-GAAP earnings per diluted share are important measures in the evaluation of the Company’s performance and uses these measures to better understand and evaluate our business.
The non-GAAP financial measures reflect adjustments for the following items:
Constant currency revenue adjustments
Some of our sales agreements with foreign customers provide for payment in currencies other than the U.S. Dollar. These foreign currency revenues, when converted into U.S. Dollars, can vary significantly from period-to-period depending on the average and quarter-end exchange rates during a respective period. We believe that comparing these foreign currency denominated revenues by holding the exchange rates constant with the prior year period is useful to management and investors in evaluating our revenue growth rates on a period-to-period basis. We anticipate that fluctuations in foreign exchange rates and the related constant currency adjustments for calculation of our revenue growth rate will continue to occur in future periods.
Acquired tangible asset amortization
These transactions represent amortization expense in connection with business or assets acquisitions associated with acquired tangible assets and asset valuation step-ups.
Business transition and related costs
These transactions represent gains, losses, and other related costs associated with business transition plans. These items may include but are not limited to severance, relocation, consulting, leasehold exit costs, asset impairment, and other related costs to rationalize our operational footprint and optimize business results.
Acquired intangible asset amortization
These transactions represent amortization expense in connection with business or assets acquisitions associated with acquired intangible assets including, but not limited to customer relationships, intellectual property, trade names and non-competition agreements.
-2-

Acquisitions, integrations, divestitures, and related costs
These transactions represent gains, losses, and other related costs associated with acquisitions, integrations, investments, divestitures, assets impairments, and in-process research and development.
Litigation related expenses and settlements (prior definition)
These transactions represent gains, losses, and other related costs associated with certain litigation matters, which can vary in their characteristics, frequency and significance to our operating results.
Litigation related expenses and settlements (updated definition)
We have been engaged in various legal proceedings against Apple since January 2020, including various proceedings in the federal courts, various proceedings in the U.S. Patent and Trademark Office (the “PTO proceedings”), and a proceeding in the U.S. International Trade Commission (the “ITC proceeding”). Although we previously excluded only expenses relating to the ITC proceeding from the definition of “Litigation related expenses and settlements”, beginning with the first quarter of 2024, we have revised the definition of “Litigation related expenses and settlements” to exclude not only expenses relating to the ITC proceeding, but also all other Apple litigation expenses, including those relating to the federal court proceedings and the PTO proceedings. We believe all of the Apple litigation expenses are unique in nature and not indicative of the Company’s on-going operating performance, and this updated definition will provide more useful information to investors by facilitating period-to-period comparisons of our financial performance that otherwise may be obscured by the significant fluctuations in Apple-related litigation expenses.
Other adjustments
In the event there are gains, losses and other adjustments which impact period-to-period comparability and do not represent the underlying ongoing results of the business, the Company may choose to exclude these from non-GAAP earnings.
Realized and unrealized gains or losses
These transactions represent gains, losses, and other related costs associated with foreign currency denominated transactions and investments. Changes in the underlying currency rates relative to the U.S. Dollar may result in realized and unrealized foreign currency gains and losses between the time these receivables and payables arise and the time that they are settled in cash. Unrealized and realized gains and losses on investments may impact the Company’s reported results of operations for a period. These items are highly variable, difficult to predict and outside the control of those responsible for the underlying operations of the business. Other items also included here are mark-to-market gains and losses of derivative contracts that are not designated as hedging instruments or the ineffective portions of cash flow hedges.
Financing related adjustments
The Company may enter into various financial arrangements whereby costs are incurred and certain instrument features are valued and expensed accordingly but are not necessarily indicative of the on-going cash flow generation of the Company and therefore excludes these costs from non-GAAP earnings. For GAAP earnings per diluted share purposes, the Company cannot reflect the anti-dilutive impact, if applicable, in its diluted shares calculations. However, the Company believes that reflecting the anti-dilutive impact of these instruments in non-GAAP earnings per diluted share provides management and investors with useful information in evaluating the financial performance of the Company on a per share basis.
Tax impact of non-GAAP adjustments
In order to reflect the tax effected impact of the non-GAAP adjustments, the Company will adjust the non-GAAP earnings by the approximate tax impact of these adjustments.
Excess tax benefits from stock-based compensation expense
GAAP requires that excess tax benefits recognized on stock-based compensation expense be reflected in our provision for income taxes rather than paid-in capital. As these excess tax benefits may be highly variable from period-to-period, the Company may choose to exclude these tax benefits from non-GAAP earnings to facilitate comparability between periods and with peers.
-3-

Forward-Looking Non-GAAP Financial Measures
This presentation also includes certain forward-looking non-GAAP financial measures. We calculate forward-looking non-GAAP financial measures based on internal forecasts that omit certain amounts that would be included in GAAP financial measures. For instance, we exclude the impact of certain charges related to acquisitions, integrations, divestitures and related costs; business transition and related costs; litigation related expenses and settlements; realized and unrealized gains or losses; tax related adjustments; and other adjustments. We have not provided quantitative reconciliations of these forward-looking non-GAAP financial measures to the most directly comparable forward-looking GAAP financial measures because the excluded items are not available on a prospective basis without unreasonable efforts. For example, the timing of certain transactions is difficult to predict because management's plans may change. In addition, the Company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. It is probable that these forward-looking non-GAAP financial measures may be materially different from the corresponding GAAP financial measures.
Forward-Looking Statements
All statements other than statements of historical facts included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements including, in particular, the statements about our expectations regarding our fourth-quarter 2024 and updated full-year 2024 financial guidance, including GAAP and non-GAAP consolidated revenue, healthcare revenue, non-healthcare revenue, consolidated operating income and consolidated earnings per diluted share. These forward-looking statements are based on management’s current expectations and beliefs and are subject to uncertainties and factors, all of which are difficult to predict and many of which are beyond our control and could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks include, but are not limited to, those related to: our dependence on Masimo SET® and Masimo rainbow SET™ products and technologies for substantially all of our revenue; any failure in protecting our intellectual property exposure to competitors’ assertions of intellectual property claims; the highly competitive nature of the markets in which we sell our products and technologies; any failure to continue developing innovative products and technologies; our ability to successfully integrate Sound United’s brands into our business; our ability to address and expand into new markets; the lack of acceptance of any of our current or future products and technologies; obtaining regulatory approval of our current and future products and technologies; the risk that the implementation of our international realignment will not continue to produce anticipated operational and financial benefits, including a continued lower effective tax rate; the loss of our customers; the failure to retain and recruit senior management; matters relating to future board and management leadership; product liability claims exposure; a failure to obtain expected returns from the amount of intangible assets we have recorded; the maintenance of our brand; the amount and type of equity awards that we may grant to employees and service providers in the future; our ongoing litigation and related matters; the ability to effect any potential separation of our consumer business described above and to meet any of the conditions related thereto; the approval of any such potential separation by Masimo’s board of directors; the ability of any separated businesses to be successful; potential uncertainty during the pendency of any such potential separation that could affect Masimo’s financial performance; the possibility that any potential separation will not be completed within the anticipated time period or at all; the possibility that any such potential separation will not achieve its intended benefits; the possibility of disruption, including changes to existing business relationships, disputes, litigation or unanticipated costs in connection with any such potential separation; the impact on our employees; the uncertainty of the expected financial performance of Masimo prior to and following completion of any such potential separation; negative effects of the announcement or pendency of any such potential separation on the market price of Masimo’s securities and/or on the financial performance of Masimo; evolving legal, regulatory and tax regimes; changes in general economic and/or industry specific conditions; actions by third parties, including government agencies; and other factors discussed in the “Risk Factors” section of our most recent periodic reports filed with the Securities and Exchange Commission (“SEC”), including our most recent Form 10-K and Form 10-Q, all of which you may obtain for free on the SEC’s website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, even if subsequently made available by us on our website or otherwise. We do not undertake any obligation to update, amend or clarify these forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
RECONCILIATION OF HEALTHCARE GAAP TO NON-GAAP CONSTANT CURRENCY REVENUE(1):
Three Months Ended
(in millions, except percentages)September 28,
2024		September 30,
2023
GAAP healthcare revenue$343.3 $307.8 
Constant currency revenue adjustments0.6 N/A
Non-GAAP healthcare constant currency revenue$343.9 $307.8 
GAAP healthcare revenue growth %11.5 %
Non-GAAP healthcare constant currency revenue growth %11.7 %
__________________
(1)      May not foot due to rounding.

-4-

RECONCILIATION OF GAAP TO NON-GAAP CONSOLIDATED OPERATING INCOME(1):
Three Months Ended
(in millions)September 28,
2024		September 30,
2023
GAAP operating income$30.1 $25.2 
Non-GAAP adjustments:
Acquired tangible asset amortization0.8 0.9 
Acquired intangible asset amortization9.2 9.4 
Acquisitions, integrations, divestitures, and related costs4.6 10.6 
Business transition and related costs(0.5)4.2 
Litigation related expenses, settlements and awards30.4 6.0 
Other adjustments(1.9)0.5 
Total non-GAAP adjustments42.7 31.5 
Non-GAAP operating income (prior definition)$72.8 $56.9 
Litigation related expenses and settlements8.0 8.9 
Non-GAAP operating income (updated definition)$80.8 $65.9 
__________________
(1)     May not foot due to rounding.

RECONCILIATION OF GAAP TO NON-GAAP NET INCOME AND NET INCOME PER DILUTED SHARE(1):
Three Months Ended
September 28,
2024		September 30,
2023
(in millions, except per diluted share amounts)$Per Diluted Share$Per Diluted Share
GAAP net income$9.8 $0.18 $10.6 $0.20 
Non-GAAP adjustments:
Acquired tangible asset amortization0.8 0.01 0.9 0.02 
Acquired intangible asset amortization9.2 0.17 9.4 0.18 
Acquisitions, integrations, divestitures, and related costs4.6 0.09 10.6 0.20 
Business transition and related costs(0.5)(0.01)4.2 0.08 
Litigation related expenses, settlements and awards30.4 0.56 6.0 0.11 
Other adjustments(1.9)(0.03)0.5 0.01 
Realized and unrealized gains or losses9.2 0.17 (1.0)(0.02)
Financing related adjustments0.5 0.01 0.5 0.01 
Tax impact of non-GAAP adjustments(13.8)(0.25)(8.0)(0.15)
Excess tax benefits from stock-based compensation expense(1.6)(0.03)(0.2)— 
Total non-GAAP adjustments37.1 0.68 22.9 0.42 
Non-GAAP net income (prior definition)$46.8 $0.86 $33.7 $0.63 
Litigation related expenses and settlements8.0 0.15 8.9 0.17 
Tax impact of non-GAAP adjustments(1.9)(0.04)(2.1)(0.04)
Non-GAAP net income (updated definition)$52.9 $0.98 $40.5 $0.75 
Weighted average shares outstanding-diluted54.3 53.9 
__________________
(1)      May not foot due to rounding.
-5-

MASIMO CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited, in millions)
September 28,
2024		December 30,
2023
ASSETS
Current assets
Cash and cash equivalents$158.5 $163.0 
Accounts receivable, net of allowance for credit losses371.0 355.5 
Inventories569.9 545.0 
Other current assets180.5 168.4 
Total current assets1,279.9 1,231.9 
Lease receivable, non-current64.2 71.4 
Deferred costs and other contract assets59.6 57.3 
Property and equipment, net417.9 424.4 
Customer relationships, net169.0 177.7 
Acquired technologies, net115.3 129.4 
Other intangible assets, net120.9 112.8 
Trademarks235.6 232.4 
Goodwill412.5 407.7 
Deferred tax assets107.1 107.2 
Other non-current assets105.8 89.3 
Total assets$3,087.8 $3,041.5 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities
Accounts payable$280.8 $251.5 
Accrued compensation76.0 62.6 
Deferred revenue and other contract liabilities, current84.5 87.3 
Other current liabilities196.3 162.4 
Total current liabilities637.6 563.8 
Long-term debt733.2 871.7 
Deferred tax liabilities111.3 111.7 
Other non-current liabilities142.5 129.5 
Total liabilities1,624.6 1,676.7 
Commitments and contingencies
Stockholders’ equity
Common stock0.1 0.1 
Treasury stock(1,169.2)(1,169.2)
Additional paid-in capital828.4 783.4 
Accumulated other comprehensive loss(36.6)(45.3)
Retained earnings1,840.5 1,795.8 
Total stockholders’ equity1,463.2 1,364.8 
Total liabilities and stockholders’ equity$3,087.8 $3,041.5 


-6-

MASIMO CORPORATION
 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited, in millions, except per share amounts)
Three Months EndedNine Months Ended
September 28,
2024		September 30,
2023		September 28,
2024		September 30,
2023
Revenue
$504.6 $478.9 $1,493.7 $1,499.2 
Cost of goods sold241.4 244.1 734.0 758.4 
Gross profit263.2 234.8 759.7 740.8 
Operating expenses:
Selling, general and administrative184.8 156.1 522.2 504.1 
Research and development48.3 46.5 145.1 137.2 
Impairment charge— 7.0 — 7.0 
Total operating expenses233.1 209.6 667.3 648.3 
Operating income30.1 25.2 92.4 92.5 
Non-operating loss(18.5)(11.2)(36.0)(27.5)
Income before provision for income taxes11.6 14.0 56.4 65.0 
Provision for income taxes1.8 3.4 11.7 17.4 
Net income$9.8 $10.6 $44.7 $47.6 
Net income per share:
Basic$0.18 $0.20 $0.84 $0.90 
Diluted$0.18 $0.20 $0.82 $0.88 
Weighted-average shares used in per share calculations:
Basic53.4 52.8 53.2 52.8 
Diluted54.3 53.9 54.3 53.9 
The following table presents details of the stock-based compensation expense (benefit) that is included in each functional line item in the condensed consolidated statements of operations (in millions):
Three Months EndedNine Months Ended
September 28,
2024		September 30,
2023		September 28,
2024		September 30,
2023
Cost of goods sold$0.3 $0.2 $0.8 $0.8 
Selling, general and administrative2.2 (2.4)17.0 (7.1)
Research and development4.0 1.1 11.8 3.9 
Total$6.5 $(1.1)$29.6 $(2.4)

-7-

MASIMO CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited, in millions)
Nine Months Ended
September 28,
2024		September 30,
2023
Cash flows from operating activities:
Net income$44.7 $47.6 
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation and amortization72.2 75.8 
Stock-based compensation expense29.6 (2.4)
(Gain) loss on disposal of equipment, intangibles and other assets(0.3)0.6 
Provision for credit losses0.9 1.1 
Amortization of debt issuance cost1.4 1.4 
Impairment charge— 7.0 
Changes in operating assets and liabilities:
(Increase) decrease in accounts receivable(9.4)84.8 
(Increase) decrease in inventories(40.1)(93.1)
(Increase) decrease in other current assets(12.3)(14.6)
(Increase) decrease in lease receivable, net7.1 (6.8)
(Increase) decrease in deferred costs and other contract assets(2.3)(2.9)
(Increase) decrease in other non-current assets0.1 (42.0)
Increase (decrease) in accounts payable29.4 3.6 
Increase (decrease) in accrued compensation13.3 (32.8)
Increase (decrease) in accrued liabilities24.6 (19.5)
Increase (decrease) in income tax payable(1.0)(7.1)
Increase (decrease) in deferred revenue and other contract-related liabilities(3.0)(6.2)
Increase (decrease) in other non-current liabilities(9.0)22.5 
Net cash provided by (used in) operating activities145.9 17.0 
Cash flows from investing activities:
Purchases of property and equipment(24.5)(33.1)
Proceeds from sale of property and equipment13.5 — 
Increase in intangible assets(23.6)(29.3)
Business combinations, net of cash acquired— 7.5 
Other strategic investing activities(0.1)(1.0)
Net cash (used in) provided by investing activities(34.7)(55.9)
Cash flows from financing activities:
Borrowings under line of credit72.7 139.5 
Repayments on line of credit(207.2)(154.3)
Proceeds from issuance of common stock21.4 6.7 
Payroll tax withholdings on behalf of employees for vested equity awards(6.0)(12.7)
Net cash (used in) provided by financing activities(119.1)(20.8)
Effect of foreign currency exchange rates on cash3.4 (17.6)
Net decrease in cash, cash equivalents and restricted cash(4.5)(77.3)
Cash, cash equivalents and restricted cash at beginning of period168.2 209.6 
Cash, cash equivalents and restricted cash at end of period$163.7 $132.3 

-8-

About Masimo
Masimo (Nasdaq: MASI) is a global technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. In addition, Masimo Consumer Audio is home to eight legendary audio brands, including Bowers & Wilkins®, Denon®, Marantz®, and Polk Audio®. Our mission is to improve life, improve patient outcomes; and reduce the cost of care. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies. Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates, improve CCHD screening in newborns, and, when used for continuous monitoring with Masimo Patient SafetyNet™ in post-surgical wards, reduce rapid response team activations, ICU transfers, and costs. Masimo SET® is estimated to be used on more than 200 million patients in leading hospitals and other healthcare settings around the world, and is the primary pulse oximetry at all 10 U.S. hospitals as ranked in the 2024 Newsweek World’s Best Hospitals listing. In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVi®), RPVi™ (rainbow® PVi), and Oxygen Reserve Index (ORi™). In 2013, Masimo introduced the Root® Patient Monitoring and Connectivity Platform, built from the ground up to be as flexible and expandable as possible to facilitate the addition of other Masimo and third-party monitoring technologies; key Masimo additions include Next Generation SedLine® Brain Function Monitoring, O3® Regional Oximetry, and ISA™ Capnography with NomoLine® sampling lines. Masimo’s family of continuous and spot-check monitoring Pulse CO-Oximeters® includes devices designed for use in a variety of clinical and non-clinical scenarios, including tetherless, wearable technology, such as Radius-7®, Radius PPG® and Radius VSM™, portable devices like Rad-67®, fingertip pulse oximeters like MightySat® Rx, and devices available for use both in the hospital and at home, such as Rad-97® and the Masimo W1® Medical Watch. Masimo hospital and home automation and connectivity solutions are centered around the Masimo Hospital Automation™ platform, and include Iris® Gateway, iSirona™, Patient SafetyNet, Replica®, Halo ION®, UniView®, UniView :60™, and Masimo SafetyNet™. It’s growing portfolio of health and wellness solutions includes Radius T0® and Masimo W1™. Additional information about Masimo and its products may be found at www.masimo.com.
RPVi has not received FDA 510(k) clearance and is not available for sale in the United States. The use of the trademark Patient SafetyNet is under license from University HealthSystem Consortium.

# # #
Investor Contact: Eli KammermanMedia Contact: Evan Lamb
(949) 297-7077(949) 396-3376
ekammerman@masimo.comelamb@masimo.com
Media Contact: Longacre Square Partners
masimo@longacresquare.com
Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI and ORI are trademarks or registered trademarks of Masimo Corporation.
-9-
Third Quarter 2024 Earnings November 5, 2024 1

 
Safe Harbor Statement Forward-Looking Statements: This presentation contains forward-looking statements within the meaning of federal securities laws, including, among others, statements about our expectations, plans, strategies or prospects. We generally use the words “may,” “will,” “expect,” “believe,” “anticipate,” “plan,” “estimate,” “project,” “assume,” “guide,” “target,” “forecast,” “see,” “seek,” “can,” “should,” “could,” “would,” “intend,” “predict,” “potential,” “strategy,” “is confident that,” “future,” “opportunity,” “work toward,” and similar expressions to identify forward- looking statements. All statements other than statements of historical or current fact are, or may be deemed to be, forward-looking statements. Such statements are based upon the current beliefs, expectations and assumptions of management and are subject to significant risks, uncertainties and changes in circumstances that could cause actual results to differ materially from the forward-looking statements. Forward-looking statements speak only as of the date they are made, and we disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers of this presentation are cautioned not to rely on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this presentation. The risks and uncertainties that may cause actual results to differ materially from Masimo’s current expectations are more fully described in Masimo’s reports filed with the U.S. Securities and Exchange Commission (SEC), including our most recent Form 10-K and Form 10-Q. Copies of these filings, as well as subsequent filings, are available online at www.sec.gov, www.masimo.com or upon request. Non-GAAP Financial Measures: The non-GAAP financial measures contained herein are a supplement to the corresponding financial measures prepared in accordance with U.S. GAAP. The non-GAAP financial measures presented exclude certain items that are more fully described in the Appendix. Management believes that adjustments for these items assist investors in making comparisons of period-to-period operating results. Furthermore, management also believes that these items are not indicative of the Company’s on-going core operating performance. These non-GAAP financial measures have certain limitations in that they do not reflect all of the costs associated with the operations of the Company’s business as determined in accordance with GAAP. Therefore, investors should consider non-GAAP financial measures in addition to, and not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. The non-GAAP financial measures presented by the Company may be different from the non-GAAP financial measures used by other companies. The Company has presented the following non-GAAP financial measures to assist investors in understanding the Company’s core net operating results on an on-going basis: non-GAAP revenue (constant currency), pro-forma non-GAAP revenue (constant currency), pro-forma non-GAAP revenue growth (constant currency), non-GAAP gross profit/margin %, non-GAAP SG&A expense (prior definition and updated definition), non-GAAP R&D expense, non-GAAP litigation settlements and awards, non-GAAP impairment charge, non-GAAP operating expense % (prior definition and updated definition), non-GAAP operating profit/margin % (prior definition and updated definition), non-GAAP non-operating income (expense), non-GAAP provision for income taxes (prior definition and updated definition), non-GAAP net income (loss) (prior definition and updated definition), non-GAAP net income (loss) per share (prior definition and updated definition). These non-GAAP financial measures may also assist investors in making comparisons of the company’s core operating results with those of other companies. Management believes these non-GAAP financial measures are important in the evaluation of the Company’s performance and uses these measures to better understand and evaluate our business. For additional financial details, including GAAP to non-GAAP reconciliations, please visit the Investor Relations section of the Company’s website at www.investor.masimo.com to access Supplementary Financial Information. Forward-Looking Non-GAAP Financial Measures: This presentation also includes certain forward-looking non-GAAP financial measures. We calculate forward-looking non-GAAP financial measures based on internal forecasts that omit certain amounts that would be included in GAAP financial measures. For instance, we exclude the impact of certain charges related to acquisitions, integrations, divestitures and related costs; business transition and related costs; litigation related expenses and settlements; realized and unrealized gains or losses; tax related adjustments; and other adjustments. We have not provided quantitative reconciliations of these forward-looking non-GAAP financial measures to the most directly comparable forward-looking GAAP financial measures because the excluded items are not available on a prospective basis without unreasonable efforts. For example, the timing of certain transactions is difficult to predict because management's plans may change. In addition, the Company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. It is probable that these forward-looking non-GAAP financial measures may be materially different from the corresponding GAAP financial measures. 2

 
Notes: 1. The information presented is based on calculations holding exchange rates constant with the prior year period for comparison purposes 2. See Appendix for reconciliation of GAAP and non-GAAP measures, including constant currency and pro forma measures. 3. Represents updated guidance provided November 5, 2024. 4. Financial guidance includes forward-looking non-GAAP financial measures for which reconciliations to the most directly comparable GAAP financial measures are not available without unreasonable efforts. See “Forward-Looking Non-GAAP Financial Measures" on slide 2, which identifies the information that is unavailable without unreasonable efforts and provides additional information. It is probable that forward-looking non-GAAP financial measures may be materially different from the corresponding GAAP financial measures. 5. Represents the midpoint of the prior guidance range provided on August 6, 2024. Executive Summary Third Quarter 2024 • Consolidated revenue was $505 million, representing 5% growth on a reported and constant currency(1) basis. o Healthcare revenue was $343 million, representing 12% growth on a reported and constant currency(1) basis. o Non-Healthcare revenue was $161 million, representing a 6% decline on a reported and constant currency(1) basis. • Non-GAAP(2) gross margin was 53.9%, representing an improvement of 350 basis points versus prior year. o Healthcare gross margin was 62.9%, representing an improvement of 260 basis points. o Non-Healthcare gross margin was 34.6%, representing an improvement of 200 basis points. • Non-GAAP(2) Operating Margin was 16%, representing an improvement of 230 basis points versus prior year. The operating margin performance was driven by improved gross margins and effective expense management across the organization; partially offset by year-over- year expense headwinds due to the return of performance-based compensation to normal levels in 2024. • Non-GAAP(2) EPS was $0.98, representing 31% growth; favorable to guidance midpoint(3) by $0.15 (or 18%). Year-to-Date Through the Third Quarter 2024 • Consolidated revenue was $1,494 million, representing 0% growth on a reported and constant currency(1) basis. o Healthcare revenue was $1,027 million, representing 10% growth on a reported and constant currency(1) basis. o Non-Healthcare revenue was $467 million, representing a 17% decline on a reported basis and a 16% decline on a constant currency(1) basis. • Non-GAAP(2) gross margin was 53.3%, representing an improvement of 250 basis points versus prior year. o Healthcare gross margin was 62.5%, representing an improvement of 160 basis points. o Non-Healthcare gross margin was 33.0%, representing a decline of 110 basis points. • Non-GAAP(2) Operating Margin was 15%, which was flat to prior year. The operating margin performance was driven by improved gross margins and effective expense management across the organization; offset by year-over-year expense headwinds due to the return of performance-based compensation to normal levels in 2024. • Non-GAAP(2) EPS was $2.61, representing 3% growth. Full Year 2024 Updated Guidance(3,4) • Consolidated revenue range of $2,075 million to $2,105 million; decreasing $20 million from the midpoint of the prior guidance(5) range. o Healthcare revenue range of $1,390 million to $1,400 million; representing no change from the midpoint of the prior guidance(5) range. o Non-Healthcare revenue range of $685 million to $705 million; decreasing $20 million from the midpoint of the prior guidance(5) range. • Non-GAAP(4) EPS range of $3.95 to $4.10; increasing $0.13 from the midpoint of the prior guidance(5) range.

 
As Reported Constant Currency Healthcare Revenue $343 $340 1% $308 12% 12% Non-Healthcare Revenue $161 $165 (2%) $171 (6%) (6%) Consolidated Revenue $505 $505 (0%) $479 5% 5% GAAP Gross Profit $263 $261 1% $235 12% GAAP Gross Margin 52% 52% 50 bps 49% 320 bps Non-GAAP Gross Profit $272 $270 1% $241 13% Non-GAAP Gross Margin 54% 53% 40 bps 50% 350 bps GAAP Operating Profit $30 $29 4% $25 19% GAAP Operating Margin 6% 6% 30 bps 5% 70 bps Non-GAAP Operating Profit $81 $72 12% $66 23% Non-GAAP Operating Margin 16% 14% 170 bps 14% 230 bps GAAP Earnings Per Share $0.18 $0.25 (28%) $0.20 (10%) Non-GAAP Earnings Per Share $0.98 $0.83 18% $0.75 31% vs. Prior Year ($ in millions; except EPS) Q3 2024 Actual Q3 2023 Actual Q3 2024 Guidance(2) vs. Guidance Midpoint Third Quarter 2024 Actual vs. Guidance and Prior Year(1) For the third quarter 2024, Non-GAAP operating margin was 16%, representing a year-over-year improvement of 230 basis points. The operating margin performance was driven by improved gross margins and effective expense management across the organization; partially offset by year-over-year expense headwinds due to the return of performance-based compensation to normal levels in 2024. 4 Notes: 1. See Appendix for reconciliation of GAAP and non-GAAP measures, including constant currency and pro forma measures. 2. Represents the midpoint of the guidance range provided on August 6, 2024. All growth comparisons in this presentation relate to the corresponding period of prior fiscal year unless otherwise noted. Numbers may not foot due to rounding.

 
32.6% 34.6% 2023 2024 Financial Performance | Third Quarter 2024 vs. Prior Year(1) 60.3% 62.9% 2023 2024 Third Quarter Healthcare Gross Margin(2) % of Healthcare Revenue Third Quarter Non-Healthcare Gross Margin(2) % of Non-Healthcare Revenue Third Quarter Non-GAAP Earnings Per Share(2) $ per share $308 $343 2023 2024 Third Quarter Healthcare Revenue $MM $171 $161 2023 2024 Third Quarter Non-Healthcare Revenue $MM Third Quarter Consolidated Revenue $MM $479 $505 2023 2024 $0.75 $0.98 2023 2024 Notes: 1. The information presented is based on calculations holding exchange rates constant with the prior year period for comparison purposes. 2. See Appendix for reconciliation of GAAP and non-GAAP measures, including constant currency and pro forma measures.

 
As Reported Constant Currency Healthcare Revenue $1,027 $936 10% 10% Non-Healthcare Revenue $467 $564 (17%) (16%) Consolidated Revenue $1,494 $1,499 (0%) 0% GAAP Gross Profit $760 $741 3% GAAP Gross Margin 51% 49% 150 bps Non-GAAP Gross Profit $797 $762 5% Non-GAAP Gross Margin 53% 51% 250 bps GAAP Operating Profit $92 $93 (0%) GAAP Operating Margin 6% 6% 0 bps Non-GAAP Operating Profit $222 $221 0% Non-GAAP Operating Margin 15% 15% 0 bps GAAP Earnings Per Share $0.82 $0.88 (7%) Non-GAAP Earnings Per Share $2.61 $2.54 3% vs. Prior Year ($ in millions; except EPS) YTD 2024 Actual YTD 2023 Actual Year-to-Date 2024 Actual vs. Prior Year(1) 6Notes: 1. See Appendix for reconciliation of GAAP and non-GAAP measures, including constant currency and pro forma measures. All growth comparisons in this presentation relate to the corresponding period of prior fiscal year unless otherwise noted. Numbers may not foot due to rounding. For the year-to-date through the third quarter 2024, Non-GAAP operating margin was 15%. The operating margin performance was driven by improved gross margins and effective expense management across the organization; offset by year-over-year expense headwinds due to the return of performance-based compensation to normal levels in 2024.

 
34.1% 33.0% 2023 2024 Financial Performance | Year-to-Date 2024 Actual vs. Prior Year 60.9% 62.5% 2023 2024 Year-to-Date Through the Third Quarter Healthcare Gross Margin(2) % of Healthcare Revenue Notes: 1. The information presented is based on calculations holding exchange rates constant with the prior year period for comparison purposes. 2. See Appendix for reconciliation of GAAP and non-GAAP measures, including constant currency and pro forma measures. Year-to-Date Through the Third Quarter Non-Healthcare Gross Margin(2) % of Non-Healthcare Revenue Year-to-Date Through the Third Quarter Non-GAAP Earnings Per Share(2) $ per share $936 $1,027 2023 2024 Year-to-Date Through the Third Quarter Healthcare Revenue $MM $564 $467 2023 2024 Year-to-Date Through the Third Quarter Non-Healthcare Revenue $MM Year-to-Date Through the Third Quarter Consolidated Revenue $MM $1,499 $1,494 2023 2024 0% Growth(1,2) $2.54 $2.61 2023 2024

 
$1,435 $1,652 2023 2024 Healthcare Performance | Year-to-Date 2024 Actual vs. Prior Year Year-to-Date Through the Third Quarter Total Healthcare Revenue $MM, shown as reported Year-to-Date Through the Third Quarter Unrecognized Contract Revenue(2) $MM, shown as reported Year-to-Date Through the Third Quarter Driver Installed Base(3) # of Units (MM) Year-to-Date Through the Third Quarter Incremental Value of New Contracts(1) $MM, shown as reported Year-to-Date Through the Third Quarter Consumable & Service Revenue $MM, shown as reported Year-to-Date Through the Third Quarter Notes: 1. Represents total contract revenue over the multi-year term of the contracts. Includes contracts with new customers and incremental new contracted business with existing customers. Management uses this information to analyze business trends. 2. Represents Masimo’s unrecognized contract revenue (as defined in Masimo’s Annual Report and Form 10-K, filed on February 28, 2024). 3. Represents estimated installed base of non-invasive technology boards and instruments, excluding handheld and fingertip pulse oximeters, shipped over a rolling 10-year period. 4. The information presented is based on calculations holding exchange rates constant with the prior year period for comparison purposes. 5. Reflects annualized figures based on consumable & service revenue for each respective performance period. $936 $1,027 2023 2024 $799 $922 2023 2024 Consumable & Service Revenue Per Driver Annualized Revenue $ per Driver(5) $285 $318 2023 2024 $419 $473 2023 2024 2.54 2.60 2023 2024 8

 
2024 Financial Guidance | November 5, 2024(1) ($ in millions; except EPS) Low - High Low - High Healthcare Revenue $363 - $373 $1,390 - $1,400 Non-Healthcare Revenue $218 - $238 $685 - $705 Consolidated Revenue $581 - $611 $2,075 - $2,105 Healthcare Revenue Growth (Constant Currency)(2) 7% - 10% 9% - 10% Non-Healthcare Revenue Growth (Constant Currency)(2) 3% - 13% (11%) - (9%) Consolidated Revenue Growth (Constant Currency)(2) 5% - 11% 2% - 3% Non-GAAP Operating Profit $103 - $114 $325 - $336 Non-GAAP Operating Margin 18% - 19% 16% - 16% Non-GAAP Earnings Per Share $1.35 - $1.50 $3.95 - $4.10 Non-GAAP EPS Growth 8% - 20% 4% - 8% FY 2024 GuidanceQ4 2024 Guidance 9 Notes: 1. Financial guidance includes forward-looking non-GAAP financial measures for which reconciliations to the most directly comparable GAAP financial measures are not available without unreasonable efforts. See “Forward-Looking Non-GAAP Financial Measures" on slide 2, which identifies the information that is unavailable without unreasonable efforts and provides additional information. It is probable that forward-looking non-GAAP financial measures may be materially different from the corresponding GAAP financial measures. 2. The information presented is based on calculations holding exchange rates constant with the prior year period for comparison purposes. All growth comparisons in this presentation relate to the corresponding period of prior fiscal year unless otherwise noted. Numbers may not foot due to rounding.

 
Appendix GAAP to Non-GAAP Reconciliations 10

 
Consolidated Income Statement Notes: (1) Totals may not foot due to rounding. Annual reported amounts may vary from amounts previously reported due to rounding conventions. (2) Effective fiscal year 2024, we are updating our non-GAAP financial measures to exclude the impact of all expenses related to our litigation with Apple. Masimo had previously only excluded the expenses related to the U.S. International Trade Commission litigation against Apple. Masimo believes all Apple litigation expenses are unique in nature and not indicative of the Company’s on-going operating performance and is therefore excluding them from its non-GAAP financial measures. (3) Guidance provided November 5, 2024. Financial guidance includes forward-looking non-GAAP financial measures for which reconciliations to the most directly comparable GAAP financial measures are not available without unreasonable efforts. See “Forward-Looking Non-GAAP Financial Measures" on slide 2, which identifies the information that is unavailable without unreasonable efforts and provides additional information. It is probable that forward-looking non-GAAP financial measures may be materially different from the corresponding GAAP financial measures. (Unaudited; in millions, except per share data) (1),(2) Quarterly Performance Year to Date Full Year Q4 2024 Guidance (3) FY 2024 Guidance (3) Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 YTD 2023 YTD 2024 FY 2023 Low High Low High GAAP revenue $565.0 $455.3 $478.9 $548.9 $492.8 $496.3 $504.6 $1,499.2 $1,493.7 $2,048.1 $581 $611 $2,075 $2,105 GAAP gross profit $284.8 $221.2 $234.8 $262.7 $241.7 $254.8 $263.2 $740.8 $759.7 $1,003.5 Acquired intangible asset amortization 5.2 5.4 6.2 4.9 4.9 4.8 4.9 16.8 14.6 21.7 Acquisitions, integrations, divestitures, and related costs - - - - 0.0 0.1 - - 0.1 - Business transition and related costs - - - 6.0 6.2 9.2 5.5 - 20.9 6.0 Other adjustments 2.5 0.9 0.5 (0.0) 3.1 0.0 (1.9) 3.9 1.3 3.9 Non-GAAP gross profit $292.6 $227.6 $241.4 $273.6 $255.9 $268.9 $271.8 $761.6 $796.6 $1,035.1 $303 $320 $1,100 $1,116 GAAP selling, general and administrative expenses $196.3 $151.7 $156.1 $159.8 $159.9 $177.5 $184.8 $504.1 $522.2 $664.0 Acquired tangible asset amortization (2.2) (1.0) (0.9) (0.9) (0.8) (0.8) (0.8) (4.1) (2.4) (5.0) Acquired intangible asset amortization (4.7) (4.2) (3.3) (4.3) (4.3) (4.3) (4.3) (12.2) (13.0) (16.5) Acquisitions, integrations, divestitures, and related costs (3.5) (3.9) (3.6) (2.1) (6.0) (6.0) (4.6) (10.9) (16.7) (13.1) Business transition and related costs - - (2.4) (2.3) (1.3) (1.2) 6.8 (2.4) 4.4 (4.6) Litigation related expenses and settlements (19.1) (13.4) (6.0) 7.9 2.3 (9.3) (30.4) (38.5) (37.5) (30.6) Non-GAAP selling, general and administrative expenses (prior definition) $166.8 $128.9 $139.8 $158.4 $149.5 $156.1 $151.4 $435.5 $457.1 $594.0 Litigation related expenses and settlements (11.6) (9.8) (8.9) (13.1) (8.1) (7.9) (8.0) (30.3) (24.0) (43.4) Non-GAAP selling, general and administrative expenses (updated definition) $155.2 $119.1 $130.9 $145.3 $141.5 $148.2 $143.4 $405.2 $433.0 $550.6 GAAP research and development expenses $50.5 $40.2 $46.5 $38.0 $47.8 $49.0 $48.3 $137.2 $145.1 $175.2 Acquisitions, integrations, divestitures, and related costs (0.2) (0.2) - - - - - (0.4) - (0.4) Business transition and related costs - - (1.8) (1.4) (1.4) (1.1) (0.8) (1.8) (3.3) (3.2) Non-GAAP research and development expenses $50.2 $40.1 $44.7 $36.5 $46.5 $47.8 $47.6 $135.1 $141.9 $171.6 GAAP litigation settlements and awards $0.0 $0.0 $0.0 $17.8 $0.0 $0.0 $0.0 $0.0 $0.0 $17.8 Litigation related expenses and settlements - - - (17.8) - - - - - (17.8) Non-GAAP litigation settlements and awards $0.0 $0.0 $0.0 $0.0 $0.0 $0.0 $0.0 $0.0 $0.0 $0.0 GAAP impairment charge $0.0 $0.0 $7.0 $3.0 $0.0 $0.0 $0.0 $7.0 $0.0 $10.0 Acquisition, integration and related costs - - (7.0) (3.0) - - - (7.0) - (10.0) Non-GAAP impairment charge $0.0 $0.0 $0.0 $0.0 $0.0 $0.0 $0.0 $0.0 $0.0 $0.0 GAAP operating expenses $246.8 $191.9 $209.6 $218.6 $207.7 $226.5 $233.1 $648.3 $667.3 $867.0 Acquired tangible asset amortization (2.2) (1.0) (0.9) (0.9) (0.8) (0.8) (0.8) (4.1) (2.4) (5.0) Acquired intangible asset amortization (4.7) (4.2) (3.3) (4.3) (4.3) (4.3) (4.3) (12.2) (13.0) (16.5) Acquisitions, integrations, divestitures, and related costs (3.7) (4.0) (10.6) (5.1) (6.0) (6.0) (4.6) (18.3) (16.7) (23.5) Business transition and related costs - - (4.2) (3.7) (2.7) (2.3) 6.0 (4.2) 1.1 (7.9) Litigation related expenses and settlements (19.1) (13.4) (6.0) (9.9) 2.3 (9.3) (30.4) (38.5) (37.5) (48.4) Non-GAAP operating expenses (prior definition) $217.1 $169.0 $184.6 $194.9 $196.0 $203.8 $199.0 $570.6 $598.8 $765.6 Litigation related expenses and settlements (11.6) (9.8) (8.9) (13.1) (8.1) (7.9) (8.0) (30.3) (24.0) (43.4) Non-GAAP operating expenses (updated definition) $205.5 $159.2 $175.6 $181.8 $187.9 $196.0 $191.0 $540.3 $574.9 $722.1 GAAP operating profit $38.0 $29.3 $25.2 $44.1 $34.0 $28.3 $30.1 $92.5 $92.4 $136.5 Acquired tangible asset amortization 2.2 1.0 0.9 0.9 0.8 0.8 0.8 4.1 2.4 5.0 Acquired intangible asset amortization 9.9 9.6 9.4 9.1 9.3 9.1 9.2 29.0 27.6 38.1 Acquisitions, integrations, divestitures, and related costs 3.7 4.0 10.6 5.1 6.0 6.1 4.6 18.3 16.7 23.5 Business transition and related costs - - 4.2 9.7 8.8 11.4 (0.5) 4.2 19.8 13.9 Litigation related expenses and settlements 19.1 13.4 6.0 9.9 (2.3) 9.3 30.4 38.5 37.5 48.4 Other adjustments 2.5 0.9 0.5 (0.0) 3.1 0.0 (1.9) 3.9 1.3 3.9 Non-GAAP operating profit (prior definition) $75.5 $58.6 $56.9 $78.6 $59.9 $65.1 $72.8 $191.0 $197.7 $269.6 Litigation related expenses and settlements 11.6 9.8 8.9 13.1 8.1 7.9 8.0 30.3 24.0 43.4 Non-GAAP operating profit (updated definition) $87.1 $68.4 $65.9 $91.7 $67.9 $72.9 $80.8 $221.4 $221.6 $313.0 $103 $114 $325 $336

 
Consolidated Income Statement Notes: (1) Totals may not foot due to rounding. Annual reported amounts may vary from amounts previously reported due to rounding conventions. (2) Effective fiscal year 2024, we are updating our non-GAAP financial measures to exclude the impact of all expenses related to our litigation with Apple. Masimo had previously only excluded the expenses related to the U.S. International Trade Commission litigation against Apple. Masimo believes all Apple litigation expenses are unique in nature and not indicative of the Company’s on-going operating performance and is therefore excluding them from its non-GAAP financial measures. (3) Guidance provided November 5, 2024. Financial guidance includes forward-looking non-GAAP financial measures for which reconciliations to the most directly comparable GAAP financial measures are not available without unreasonable efforts. See “Forward-Looking Non-GAAP Financial Measures" on slide 2, which identifies the information that is unavailable without unreasonable efforts and provides additional information. It is probable that forward-looking non-GAAP financial measures may be materially different from the corresponding GAAP financial measures. (Unaudited; in millions, except per share data) (1),(2) Quarterly Performance Year to Date Full Year Q4 2024 Guidance (3) FY 2024 Guidance (3) Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 YTD 2023 YTD 2024 FY 2023 Low High Low High GAAP non-operating income (expense) ($11.8) ($4.5) ($11.2) ($20.9) ($9.1) ($8.4) ($18.5) ($27.5) ($36.0) ($48.4) Realized and unrealized gains or losses 0.7 (6.5) (1.0) 8.0 (2.1) (1.4) 9.2 (6.8) 5.8 1.1 Financing related adjustments 0.5 0.5 0.5 0.5 0.5 0.5 0.5 1.4 1.4 1.9 Non-GAAP non-operating income (expense) ($10.7) ($10.5) ($11.6) ($12.4) ($10.7) ($9.4) ($8.8) ($32.8) ($28.9) ($45.4) ($9) ($9) ($38) ($38) GAAP provision for income taxes $4.9 $9.1 $3.4 ($10.8) $6.0 $3.9 $1.8 $17.4 $11.7 $6.6 Tax impact of non-GAAP adjustments 10.0 4.8 8.0 12.0 6.1 9.2 13.8 22.8 29.0 34.8 Excess tax benefits from stock-based compensation 2.4 0.5 0.2 (0.2) 1.3 2.0 1.6 3.1 4.9 2.9 Tax related adjustments - - - 8.2 - - - - - 8.2 Non-GAAP provision for income taxes (prior definition) $17.4 $14.4 $11.5 $9.3 $13.4 $15.1 $17.2 $43.3 $45.7 $52.6 Tax impact of non-GAAP adjustments 2.7 2.3 2.1 3.1 1.9 1.9 1.9 7.2 5.7 10.3 Non-GAAP provision for income taxes (updated definition) $20.1 $16.7 $13.6 $12.4 $15.3 $16.9 $19.1 $50.5 $51.3 $62.9 $21 $23 $72 $74 GAAP net income $21.3 $15.7 $10.6 $34.0 $18.9 $16.0 $9.8 $47.6 $44.7 $81.5 Acquired tangible asset amortization 2.2 1.0 0.9 0.9 0.8 0.8 0.8 4.1 2.4 5.0 Acquired intangible asset amortization 9.9 9.6 9.4 9.1 9.3 9.1 9.2 29.0 27.6 38.1 Acquisitions, integrations, divestitures, and related costs 3.7 4.0 10.6 5.1 6.0 6.1 4.6 18.3 16.7 23.5 Business transition and related costs - - 4.2 9.7 8.8 11.4 (0.5) 4.2 19.8 13.9 Litigation related expenses and settlements 19.1 13.4 6.0 9.9 (2.3) 9.3 30.4 38.5 37.5 48.4 Other adjustments 2.5 0.9 0.5 (0.0) 3.1 0.0 (1.9) 3.9 1.3 3.9 Realized and unrealized gains or losses 0.7 (6.5) (1.0) 8.0 (2.1) (1.4) 9.2 (6.8) 5.8 1.2 Financing related adjustments 0.5 0.5 0.5 0.5 0.5 0.5 0.5 1.4 1.4 1.9 Tax impact of non-GAAP adjustments (10.0) (4.8) (8.0) (12.0) (6.1) (9.2) (13.8) (22.8) (29.0) (34.8) Excess tax benefits from stock-based compensation (2.4) (0.5) (0.2) 0.2 (1.3) (2.0) (1.6) (3.1) (4.9) (2.9) Tax related adjustments - - - (8.2) - - - - - (8.2) Non-GAAP net income (prior definition) $47.5 $33.7 $33.7 $56.9 $35.8 $40.6 $46.8 $114.8 $123.2 $171.6 Litigation related expenses and settlements 11.6 9.8 8.9 13.1 8.1 7.9 8.0 30.3 24.0 43.4 Tax impact of non-GAAP adjustments (2.7) (2.3) (2.1) (3.1) (1.9) (1.9) (1.9) (7.2) (5.7) (10.3) Non-GAAP net income (updated definition) $56.3 $41.2 $40.5 $66.9 $41.9 $46.6 $52.9 $138.0 $141.4 $204.8 $74 $82 $215 $223 GAAP net income per share $0.39 $0.29 $0.20 $0.63 $0.35 $0.29 $0.18 $0.88 $0.82 $1.51 Acquired tangible asset amortization 0.04 0.02 0.02 0.02 0.02 0.01 0.01 0.08 0.04 0.09 Acquired intangible asset amortization 0.18 0.18 0.18 0.17 0.17 0.17 0.17 0.54 0.51 0.70 Acquisitions, integrations, divestitures, and related costs 0.07 0.07 0.20 0.09 0.11 0.11 0.09 0.34 0.31 0.44 Business transition and related costs 0.00 0.00 0.08 0.18 0.16 0.21 (0.01) 0.08 0.36 0.26 Litigation related expenses and settlements 0.35 0.25 0.11 0.18 (0.04) 0.17 0.56 0.71 0.69 0.89 Other adjustments 0.05 0.02 0.01 (0.00) 0.06 0.00 (0.03) 0.07 0.02 0.07 Realized and unrealized gains or losses 0.01 (0.12) (0.02) 0.15 (0.04) (0.03) 0.17 (0.12) 0.11 0.02 Financing related adjustments 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.03 0.03 0.03 Tax impact of non-GAAP adjustments (0.18) (0.09) (0.15) (0.22) (0.11) (0.17) (0.25) (0.42) (0.53) (0.64) Excess tax benefits from stock-based compensation (0.04) (0.01) (0.00) 0.00 (0.02) (0.04) (0.03) (0.06) (0.09) (0.05) Tax related adjustments 0.00 0.00 0.00 (0.15) 0.00 0.00 0.00 0.00 0.00 (0.15) Non-GAAP net income per share (prior definition) $0.87 $0.62 $0.63 $1.06 $0.66 $0.75 $0.86 $2.11 $2.27 $3.17 Litigation related expenses and settlements 0.21 0.18 0.17 0.24 0.15 0.15 0.15 0.56 0.44 0.80 Tax impact of non-GAAP adjustments (0.05) (0.04) (0.04) (0.06) (0.04) (0.04) (0.04) (0.13) (0.11) (0.19) Non-GAAP net income per share (updated definition) $1.03 $0.76 $0.75 $1.25 $0.77 $0.86 $0.98 $2.54 $2.61 $3.79 $1.35 $1.50 $3.95 $4.10 Weighted average shares outstanding - Diluted 54.4 54.4 53.9 53.7 54.2 54.3 54.3 54.2 54.3 54.1 54.7 54.7 54.5 54.5

 
Segment Reporting Notes: (1) Totals may not foot due to rounding. Annual reported amounts may vary from amounts previously reported due to rounding conventions. (2) Constant currency adjustments are intended to reflect revenue at prior year foreign exchange rates for comparison purposes (3) Guidance provided November 5, 2024. Financial guidance includes forward-looking non-GAAP financial measures for which reconciliations to the most directly comparable GAAP financial measures are not available without unreasonable efforts. See “Forward-Looking Non-GAAP Financial Measures" on slide 2, which identifies the information that is unavailable without unreasonable efforts and provides additional information. It is probable that forward-looking non-GAAP financial measures may be materially different from the corresponding GAAP financial measures. (Unaudited; in millions, except percentages) (1,2) Quarterly Performance Year to Date Full Year Q4 2024 Guidance (3) FY 2024 Guidance (3) Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 YTD 2023 YTD 2024 FY 2023 Low High Low High Revenue Healthcare 346.7 281.1 307.8 339.9 339.6 343.9 343.3 ### 935.6 1,026.8 1,275.5 363 373 1,390 1,400 Non-Healthcare 218.3 174.2 171.1 209.0 153.2 152.4 161.3 563.6 466.9 772.6 218 238 685 705 GAAP revenue $565.0 $455.3 $478.9 $548.9 $492.8 $496.3 $504.6 $1,499.2 $1,493.7 $2,048.1 $581 $611 $2,075 $2,105 Healthcare 5.6 2.0 (0.7) (1.1) 1.5 1.8 0.6 6.9 4.0 5.8 (1) (1) 3 3 Non-Healthcare N/A N/A (1.5) (3.6) 1.0 3.0 (0.1) (1.5) 3.9 N/A (2) (2) 2 2 Constant currency adjustments $5.6 $2.0 ($2.2) ($4.7) $2.5 $4.8 $0.5 $5.4 $7.9 $5.8 ($3) ($3) $5 $5 Healthcare 352.3 283.1 307.1 338.8 341.1 345.7 343.9 942.5 1,030.7 1,281.3 362 372 1,393 1,403 Non-Healthcare 218.3 174.2 169.6 205.4 154.2 155.4 161.3 562.1 470.9 772.6 216 236 687 707 Non-GAAP revenue (constant currency) $570.6 $457.3 $476.7 $544.2 $495.3 $501.1 $505.1 $1,504.6 $1,501.6 $2,053.9 $578 $608 $2,080 $2,110 Healthcare 14.0% -21.3% -5.9% -3.4% -2.1% 22.4% 11.5% -5.4% 9.7% -4.8% 7% 10% 9% 10% Non-Healthcare N/A N/A -23.0% -21.2% -29.8% -12.5% -5.7% N/A -17.2% N/A 4% 14% -11% -9% GAAP revenue growth 85.7% -19.5% -12.8% -11.0% -12.8% 9.0% 5.4% 5.7% -0.4% 0.6% 6% 11% 1% 3% Healthcare 15.8% -20.7% -6.1% -3.7% -1.6% 23.0% 11.7% -4.7% 10.2% -4.4% 7% 10% 9% 10% Non-Healthcare N/A N/A -23.6% -22.5% -29.4% -10.8% -5.8% N/A -16.5% N/A 3% 13% -11% -9% Non-GAAP revenue growth (constant currency) 87.6% -19.1% -13.2% -11.8% -12.3% 10.1% 5.5% 6.0% 0.2% 0.9% 5% 11% 2% 3% Gross profit Healthcare 214.8 169.0 185.6 207.7 211.4 214.9 215.9 569.4 642.2 777.1 Non-Healthcare 77.8 58.5 55.8 65.8 44.5 54.0 55.8 192.2 154.3 258.0 Other (7.7) (6.4) (6.6) (10.8) (14.2) (14.0) (8.5) (20.8) (36.8) (31.6) GAAP gross profit $284.8 $221.2 $234.8 $262.7 $241.7 $254.8 $263.2 $740.8 $759.7 $1,003.5 Acquired intangible asset amortization 5.2 5.4 6.2 4.9 4.9 4.8 4.9 16.8 14.6 21.7 Acquisitions, integrations, divestitures, and related costs - - - - 0.0 0.1 - - 0.1 - Business transition and related costs - - - 6.0 6.2 9.2 5.5 - 20.9 6.0 Other adjustments 2.5 0.9 0.5 (0.0) 3.1 0.0 (1.9) 3.9 1.3 3.9 GAAP adjustments $7.7 $6.4 $6.6 $10.8 $14.2 $14.0 $8.5 $20.8 $36.8 $31.6 Healthcare 214.8 169.0 185.6 207.7 211.4 214.9 215.9 569.4 642.2 777.1 228 235 871 878 Non-Healthcare 77.8 58.5 55.8 65.8 44.5 54.0 55.8 192.2 154.3 258.0 75 85 229 239 Non-GAAP gross profit $292.6 $227.6 $241.4 $273.6 $255.9 $268.9 $271.8 $761.6 $796.6 $1,035.1 $303 $320 $1,100 $1,116 Gross margin Healthcare 61.9% 60.1% 60.3% 61.1% 62.3% 62.5% 62.9% 60.9% 62.5% 60.9% Non-Healthcare 35.6% 33.6% 32.6% 31.5% 29.0% 35.4% 34.6% 34.1% 33.0% 33.4% Other -1.4% -1.4% -1.4% -2.0% -2.9% -2.8% -1.7% -1.4% -2.5% -1.5% GAAP gross margin 50.4% 48.6% 49.0% 47.9% 49.1% 51.3% 52.2% 49.4% 50.9% 49.0% Healthcare 61.9% 60.1% 60.3% 61.1% 62.3% 62.5% 62.9% 60.9% 62.5% 60.9% 63% 63% 63% 63% Non-Healthcare 35.6% 33.6% 32.6% 31.5% 29.0% 35.4% 34.6% 34.1% 33.0% 33.4% 34% 36% 33% 34% Non-GAAP gross margin 51.8% 50.0% 50.4% 49.8% 51.9% 54.2% 53.9% 50.8% 53.3% 50.5% 52% 52% 53% 53%

 
v3.24.3
Document and Entity Information Document
Nov. 05, 2024
Document Information [Line Items]  
Document Type 8-K
Document Period End Date Nov. 05, 2024
Entity Registrant Name MASIMO CORP
Entity Incorporation, State or Country Code DE
Entity File Number 001-33642
Entity Tax Identification Number 33-0368882
Entity Address, Address Line One 52 Discovery
Entity Address, City or Town Irvine,
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92618
City Area Code (949)
Local Phone Number 297-7000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.001 par value
Trading Symbol MASI
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0000937556
Amendment Flag false
Masimo (NASDAQ:MASI)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more Masimo Charts.
Masimo (NASDAQ:MASI)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more Masimo Charts.